RESUMEN
Over the past three decades, more and more antisense drugs have been approved for marketing or clinical trails. Antisense technology has become the focus of pharmaceutical research due to its unique advantages in treating diseases and strong clinical development potential. There is a big difference from traditional small molecule chemical drugs, and macromolecular protein biological drugs. Antisense drugs are a very independent drug form. Antisense drugs were initially used to treat diseases with single gene mutations, but recently they have gradually begun to be used for the treatment of common diseases. Rational antisense drug design is crucial for disease treatment based on genetics. This paper reviews the latest progress in the field of action mechanism, chemical modification and delivery strategy of antisense drugs, and analyzes the current intractable problems. It is believed that with the resolution of these problems, the research of antisense drugs can reach a new level.
RESUMEN
CypA (cyclophilin A), the main intracellular receptor of immunosuppressant CsA (cyclosporin A), is the first discovered and most abundant one in cyclophilin family and has been studied in-depth. CypA has PPIase (peptidyl-prolyl cis-trans isomerase) activity and molecular chaperone functions which enable it playing a role in correct protein folding. CypA also involves in a variety of biological functions such as immune suppression, inflammatory response, and oxidative stress response. Recent studies have found that CypA was overexpressed in many malignant tumors, and it can promote the proliferation of tumor cells, inhibit apoptosis, and mediate tumor invasion and metastasis. It may become a new diagnostic and therapeutic target of some malignant tumors in future. Copyright © 2013 by TUMOR.
RESUMEN
<p><b>AIM</b>To modify the structure of dehydroepiandrosterone (DHEA).</p><p><b>METHODS</b>Using hairy root cultures of Anisodus tanguticus to perform biotransformation of DHEA, using chromatographic and spectral techniques to isolate and identify the products.</p><p><b>RESULTS</b>(1) The MS medium without plant hormone was suitable for the growth of the hairy root. (2) DHEA was converted into five products: androst-4-ene-3, 17-dione (I); 6alpha-hydroxyandrost-4-ene-3, 17-dione (II); 6alpha, 17beta-dihydroxyandrost-4-ene-3-one (III); androst-4-ene-3, 6, 17-trione (IV) and 17beta-hydroxyandrost-4-ene-3-one (V).</p><p><b>CONCLUSION</b>It is the first time to use hairy root cultures of Anisodus tanguticus for the biotransformation of DHEA and five DHEA-related compounds were obtained.</p>